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ABSTRACT  
This paper aims to present an in-depth exploration of immunology, the influenza virus, 
vaccination, and vaccination’s effectiveness with respect to influenza. It also delves into the 
possible causes behind the large increase in early childhood deaths during the 2003-2004 
influenza season, which was a turning point in terms of influenza incident reporting. Finally, 
data analysis on the relationship between childhood flu vaccine coverage and childhood 
outpatient ILI (influenza-like illness) visits by region is presented as a measurement of 
vaccine effectiveness and identifier of trends. Although this relationship was not statistically 
significant (alpha=0.05) regionally, this simply points to alternate factors that exist among the 
relationship between vaccine coverage and outpatient visits in children. The same comparison 
made over time with national statistics did prove statistically significant (p=0.02), however, 
other variables are hypothesized to be present in this relationship as well.  
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INTRODUCTION & LITERATURE REVIEW 
There are many wonders of modern medicine that we now take for granted in the 21
st
 century. 
As such, we accept these practices as commonplace. One of these marvels is vaccination. 
Though this practice is over two centuries old, most vaccines have only been around since the 
mid-1900s, with many being widely recommended just in the last few decades. Since then, 
many controversies have arisen over vaccine safety, effectiveness, and ethics. The focus, 
though, should remain on the science behind the vaccines and what makes some more 
effective at eradicating disease than others, as well as how immunization is affecting children. 
The idea for this paper began when a study of influenza and vaccines led to the discovery of 
an unusually large number of childhood flu deaths during the 2003-2004 flu season, which 
was a turning point in terms of influenza incident reporting. This spurred the idea of 
conducting an original study on influenza vaccine effectiveness in children based on rates of 
vaccine coverage vs. outpatient rates due to flu by region. Although the study of influenza and 
vaccines is ever-growing and the body of knowledge increasing daily, this study may shed 
some light on fundamental relationships between the flu and its vaccine that are not always 
presented in an objective manner by the media.  
Immune System Components & Processes 
In order to fully delve into the science of vaccination, it is first necessary to understand their 
effect on the immune system. Generally, immunity is separated based on whether it is innate 
or adaptive. Within each of these arms of the immune system are both cellular (direct cell 
contact) and humoral (non-direct cell contact) components. Innate immunity is present from 
birth and confers protection from pathogens regardless of whether or not the body has been 
exposed to them before. In this way, it is regarded as the first line of defense. One component 
of the innate immune system includes physical, anatomical barriers such as the skin and inner 
epithelial layers. Other components are the phagocytic leukocytes, which are white blood 
cells that engulf and digest microorganisms, as well as dendritic cells, which present antigens 
on the surface of cells. Next is a special type of lymphocyte (a white blood cell) known as a 
natural killer (NK) cell. These cells are capable of destroying any and all infected cells, as 
well as tumor cells. Finally, the last aspect of the innate immune system is the presence of 
circulating plasma proteins, which are known as the complement system. These proteins 
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become activated in the presence of a pathogen, to which they bind. By interacting with 
macrophage receptors, complement proteins trigger phagocytosis (Janeway & Travers, 1996).  
In contrast, adaptive immunity is known as the body’s second line of defense against 
pathogens. It is only called into action if and when the innate immune system fails to thwart 
an invading agent, and accordingly requires more time to respond to an attack. However, they 
do retain immunological memory of the pathogens they fight, thus minimizing the time 
needed to react to future incidents. The reason behind this is the antigen-specific nature of 
innate immunity, meaning that this system is only able to recognize and respond to antigens it 
has previously been exposed to, so memory of these antigens is crucial to its success. The 
adaptive immune system’s humoral defense includes B lymphocytes or B cells, which are 
produced in the bone marrow. These cells create antibodies, plasma proteins also known as 
immunoglobulins. They either bind specifically to molecules from the invading pathogen in 
order to neutralize it or recruit other cells to destroy the pathogen by way of phagocytosis. 
Secondly, the cell-mediated immune response of the adaptive immune system is based on T 
lymphocytes or T cells, of which there are two kinds. The first is CD8+ cytotoxic T cells, 
which directly kill cells infected with viruses, while the second type, CD4+ helper T cells, 
activate B cells and macrophages to then rid the body of these pathogens (Janeway & Travers, 
1996). 
Influenza 
Technically speaking, influenza or “the flu” is an acute viral, respiratory illness caused by one 
of many flu viruses discovered in the early 1930s. This general definition, however, does not 
begin to underscore the severity and impact of this illness. Typically, the flu affects the nose, 
throat, lungs, and airways. It is different from the common cold in that it causes a 2-3 day 
fever, headaches, a lingering cough, and extreme fatigue and muscle and joint aches. Upper 
respiratory ailments such as stuffy nose, sneezing, and sore throat may occur, but are not 
always present with the flu (Chang, 2011). Although many patients will recover after about 
one week, many may still feel the effects of the flu weeks later in the form of a cough or low 
energy levels (Flu Overview, 2012).  
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Influenza is a seasonal epidemic that happens each year mainly during the late fall and winter 
months in most temperate regions and can last until early spring. For the northern hemisphere, 
the flu season runs from October to March. In tropical climates, the flu can circulate year-
round and peak once or twice during rainy seasons. Influenza spreads easily, especially in 
confined, crowded spaces like schools, nursing homes, and the workplace. Transmission 
occurs when a sick person expels infected droplets into the air by sneezing or coughing. A 
person in the area may then breathe them in and become sick. In addition, influenza can 
spread by touching contaminated surfaces and then putting one’s hands near the face (mouth, 
nose, eyes). This is why covering the mouth and nose when sneezing or coughing is so 
important, as is frequent hand-washing (Influenza, 2009).  
There are three types of influenza: A, B, and C. Types A and B are typically associated with 
seasonal epidemics, while type C is quite mild and does not generate cause for concern. Type 
A is the most common type and produces the most acute symptoms, while type B is similar to 
A with less serious symptoms. It is also slightly less common. Influenza A is further broken 
down into subtypes categorized by the two surface proteins on the virus. These antigens are 
the portions of the virus that evoke an immune response. The first protein is hemagglutinin 
(H), of which there are 17 different subtypes, while the second is neuraminidase (N), of which 
there are 10 subtypes. Together, these form the complete subtype name, such as H5N1 or 
H7N2. Within each subtype, there can be several different strains that develop in a season, 
and are simply numbered (Types, 2012).  
What makes the influenza virus so difficult to treat and prevent is its uncanny ability to 
change very often and so easily. One type of change is an antigenic drift. This is when new 
variants of a strain form each year due to genetic mistakes during the virus’s replication. The 
new variant prevails due to pressure from the immune system’s antibodies that are fighting 
the original strain. This process could cause one to catch the flu twice in the same season due 
to the slight shift in the antigen and subsequent lack of antibodies to fight it. It is important to 
note that both influenza A and B are subject to antigenic drifting (Antigenic Drift, 2011). The 
second way in which flu changes is the more noticeable antigenic shift. This phenomenon, on 
the other hand, has only been observed in type A. This is an abrupt, major change that results 
in a new virus subtype, rather than just a new strain. A shift happens when two different 
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strains simultaneously infect a cell. Antigens (hemagglutinin and/or neuraminidase) are 
exchanged and genetic material is reassorted to form the new virus subtype. Additionally, 
antigenic shift is the process that allows a strain to transfer from one animal species to another 
or from human to animal and vice versa (Antigenic Shift, 2011). 
Each year, approximately five to twenty percent of Americans become infected with 
influenza. This results in over 200,000 hospitalizations and anywhere from 3,000 to 49,000 
deaths in the U.S. annually. The reason for this wide range, which was compiled from the last 
thirty years, is the unpredictability of the flu’s severity in any given season. Also, there are 
logistical issues that contribute to this lack of accuracy in number of deaths. The first is that 
there is a lack of reporting by each state since they are not mandated to report seasonal flu 
deaths of those individuals over 18. Another problem is that influenza is not necessarily cited 
on death certificates, since fatalities often occur from complications of the flu, rather than 
simply the flu itself. One other explanation is that these flu-related deaths happen a few weeks 
post initial infection either due to a bacterial co-infection like pneumonia or exacerbation of 
an existing illness, such as heart disease or chronic obstructive pulmonary disease (COPD). In 
this case, the patient may not be tested for influenza, or the flu would not be detected in a test 
at this later point in time (Estimating, 2011). 
Often, 36,000 is quoted as an average number of U.S. influenza deaths per year, though the 
aforementioned range (3,000-49,000) is a more accurate representation of the virus’s 
irregularity. This average was gleaned from a study conducted by the Centers for Diseases 
Control and Prevention (CDC) in 2003. Because of the issues mentioned previously, the CDC 
developed a model using respiratory and circulatory (R&C) deaths as a base for influenza 
death estimates.  Specifically, it was done using Poisson regression models with national viral 
surveillance data for the 1976-1999 flu seasons. The reason why the CDC uses R&C deaths as 
opposed to pneumonia and influenza (P&I) deaths as the baseline for estimating influenza 
deaths is because R&C deaths includes any fatalities due to cardiac or respiratory 
complications that are caused by influenza. Therefore, it is more sensitive to influenza 
fatalities as a whole (Estimating, 2011).  
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Despite the fact that the flu can majorly affect those of any age, young children (under 2) the 
elderly (over 65), pregnant women, and those with chronic medical conditions have the 
highest risk for complications. This is due to their lack of protection stemming from either 
immature or compromised immune systems. Specifically, those with conditions such as 
asthma, neurological disorders, chronic lung diseases, heart disease, disorders of the blood, 
endocrine, kidney, liver or metabolism, HIV/AIDS, cancer, or morbid obesity are at high risk 
for flu-related issues (People, 2012).  
History & Classification of Flu 
It seems that influenza or “the flu” may in fact be almost as old as the father of medicine 
himself, Hippocrates. He described an illness similar to the flu in Greece in 412 B.C. This 
“sweating sickness” passed through Britain with a vengeance, causing many fatalities mainly 
due to the lack of effective treatments at the time. It was not until 1918 that the first influenza 
pandemic occurred, commonly referred to as the Spanish flu. The actual type and subtype of 
flu was later classified as A (H1N1). Over 100 million deaths have been attributed to this 
pandemic, which overwhelmed the healthcare system and caused the life expectancy in the 
U.S. to drop by twelve years. Oddly, it seemed to affect those who were young and healthy by 
causing the immune system to become overworked. Despite the public health habits put into 
place, such as requiring citizens to wear masks in public, the virus ravaged the world that 
year, stopping only after it had “burned itself out” (Walsh, 2009).  
More recent pandemics have fortunately been milder, but there is always a looming fear of 
another 1918 bout of the flu. The pandemics in 1957 (Asian flu, A/H2N2) and 1968 (Hong 
Kong flu, A/H3N2) were tame in comparison to the Spanish flu, but still carried heavy death 
tolls of about 2 million and 1 million, respectively. Most recently came the swine flu 
pandemic of 2009, which was responsible for just over 18,000 deaths worldwide (Pandemic, 
2010) (See Figure 1). Although it was the same subtype of virus as the Spanish flu and 
sickened most seriously the same group of people, the impact was not as severe. Perhaps this 
is due to the great strides in healthcare that have been made since this time in both hygiene, a 
stronger encouragement of preventative measures such as hand-washing, antiviral 
medications to curb the flu’s symptoms, respirators, and of course, vaccines. In general, strain 
A (H3N2) has caused more than double the number of deaths as other A or B strains have 
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throughout history. This reveals the virulence or disease-producing power of this virus 
subtype. One study attributed this to the fact that even small strain differences in H3N2 
viruses can mitigate the protective ability of prior antibodies to the virus. In this way, 
recurring epidemics can take place in those of all ages, being especially fatal in the elderly 
(Wright, Thompson, & Karzon, 1980).  
 
Figure 1 – Influenza Pandemics & Their Classifications 
In an article by Morens, Folkers, and Fauci (2009), a pandemic is identified not only by its 
wide geographic expanse and movement, but also by its high infection rate and the speed with 
which it spreads. Also, the population typically has little to no immunity to the disease due to 
the novelty of it, which makes it much more infectious, contagious, and severe in nature. An 
epidemic is similar to a pandemic, except that it is not necessarily global or quite as 
widespread in its extension. It is declared when the number of new cases in a population over 
a certain time exceeds the expected incidence rate. Finally, an outbreak is an epidemic that is 
limited to a small region or community (Folkers, Morens, & Fauci, 2009).  
Vaccination 
Inoculation, the process of introducing immunologically active material into an organism to 
prevent or treat disease, is believed to have begun in India or China prior to 200 B.C. 
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However, not much was known or recorded about it until much more recently. British 
physician Edward Jenner is consistently hailed as the “father of modern vaccinology,” and 
with good reason. In 1796, he developed the more specific procedure known as vaccination, 
or the “inoculation of healthy individuals with weakened or attenuated strains of disease-
causing agents to provide protection from disease” (Janeway & Travers, 1996, p. 1-1). The 
purpose of this is to induce an immune response and the subsequent production of antibodies 
so that the body will be able to fight off the actual virus or bacterium upon exposure to it. 
Jenner created a vaccine to prevent smallpox by infecting a young boy with cowpox, which 
was similar in nature to smallpox, yet much less dangerous. Since hypodermic syringes had 
not yet been developed, Jenner simply used a lancet to scratch some of the infectious 
substance into the boy’s arm. Sure enough, the boy became sick with cowpox. Almost two 
months later, Jenner inserted the smallpox virus into him and witnessed no sickness—a 
success. Thus, this form of inoculation was named a vaccine, after the Latin word “vacca,” 
meaning cow (Merino, 2010, p.13).       
By mimicking a natural infection, vaccines train the immune system to fight off the pathogen 
should it enter the body. First, the innate immune system is activated. Macrophages in the 
body recognize the antigen proteins that are contained in the vaccine solution just as if it was 
due to an actual virus. This signals the adaptive immune system to gear up, first with a surge 
of T cells binding to the infected cells. Then, B cells secrete antibodies that also help to bind 
to the antigens and neutralize the pathogen. Once the infection is overcome by the immune 
system, memory B and T cells are created so that the body can respond even quicker and 
more efficiently next time (Understanding Vaccines, 2008). 
Vaccine popularity soared in the middle of the nineteenth century with the advent of 
hypodermic syringes. It was during this time that vaccines for cholera, rabies, tetanus, typhoid 
fever, and bubonic plague were created. The twentieth century saw the addition of polio, 
measles, mumps, and rubella vaccines. Today, they are still widely attributed to the 
disappearance of smallpox and polio in the U.S., though not without opposition. Vaccines 
have been at the center of controversy in recent years due to their purported connection to 
autism in children (though this has been largely accepted as false in the medical community 
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following studies), unsafe side effects, and possible violation of religious and personal 
freedoms (Merino, 2010). 
Generally, however, vaccines are indeed viewed as a medical blessing. Not only do they act 
as a preventative measure in individuals, but they also aid in community-acquired or herd 
immunity. This occurs when an adequate amount of people in the population are vaccinated 
against a disease, thus lowering the entire group’s likelihood of falling ill. The challenge has 
always been reaching this critical number of people, though. Evidence of the consequences of 
low immunization rates have been shown in recent years. For example, in 1974, Japan 
declared it unnecessary to vaccinate against pertussis due to its declined prevalence. In just 
five years, pertussis had been able to infect 13,000 and kill 41, revealing the necessity of the 
vaccine even in modern times. Additionally, a measles outbreak occurred in the U.S. in 1989 
at a time when vaccination rates against the disease were very low. Sadly, 55,000 cases of 
measles were recorded that year, as well as 136 deaths. This too supports the notion that 
continued vaccination efforts are fundamental to keeping infection rates low (Understanding 
Vaccines, 2008).  
Overview of the Influenza Vaccine 
Specifically, a vaccine for influenza was developed in the 1950s, during a time when 
immunization was becoming increasingly popular. Prior to this in 1936, two influenza A 
vaccines were developed in embryonic eggs. One was a live virus created by Wilson Smith, 
while the other was a killed, whole virus prepared by Thomas Francis and Thomas Magill. 
Although Smith’s vaccine was later determined to have an unacceptable fail rate (20% of 
vaccinated patients contracted febrile influenza), it paved the way for live virus vaccination. 
Throughout the 1940s, Francis and Magill experimented with different types of live virus 
vaccines and ran into problems regarding mutation and inconsistent attenuation upon 
replication. It was not until 1968 that influenza vaccines were licensed for use in the U.S. Not 
until 2004 were they added to the pediatric immunization schedule (Plotkin & Plotkin, 2008). 
Today, influenza vaccines are still produced in the same manner, though in mass numbers and 
in a safer fashion. That is, chick embryos are inoculated with the chosen influenza viruses. 
Then, the mixture is left to cultivate for many weeks. Next, the flu strain is rendered inactive 
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by the addition of formaldehyde. Multi-dose vials also contain thimerosal, a mercury 
derivative, to prevent the possibility of contamination. (Though this substance has not been 
shown to cause harm, it is only used when needed as a precaution, and has not been added to 
new vaccines licensed for use in children since 2001.) (Thimerosal, 2012). The final step is 
when the three virus strains that have been added to the vaccine that year are blended into one 
vaccine through replication. Also, adjuvants, or ingredients used to improve the immune 
response, are added to the vaccine. Today, the only FDA-approved adjuvant is alum, which 
helps to slow the release of antigens and deliver them to the lymph nodes where the immune 
response is initiated (Understanding Vaccines, 2008). 
Prediction and Selection of Influenza Vaccine Strains 
Perhaps the most difficult part of the aformentioned process is the decision on which three 
strains of influenza should be included in the vaccine that season. It is standard for the vaccine 
to contain one influenza A (H3N2) virus, which is seasonal, one influenza A (H1N1) virus, 
and one influenza B virus.  Scientists must choose the specific strains within these subtypes 
(e.g., A/California/2004) to be included each year. These predictions are made based on large 
amounts of surveillance data on past flu seasons, worldwide flu activity, weather patterns, 
laborartory and clinical studies, and availability of virus strains that are suitable for 
production. This information is gleaned from 130 national influenza centers in 101 countries. 
The World Health Organization (WHO) holds two meetings per year (one in February for the 
Northern Hemisphere and one in September for the Southern Hemisphere) with the directors 
of their Collaborating Centers for Reference and Research on Influenza, as well as other 
laboratory directors. WHO then makes official recommendations on the strain choices for the 
flu vaccines, but ultimately each country has the final say on what to include in their vaccines. 
In the US, the FDA makes this decision (Selecting, 2011).  
New techniques for more advanced and accurate predictions and subsequent selection of 
influenza virus strains are beginning to surface. One such strategy was developed in 2010 by 
scientists at Rice University, led by co-authors Michael Deem and Jiankui He. Once a new 
strain appears, their method can predict whether or not the strain will become dominant, and 
thus should be included in the vaccine. Often, dominance is difficult to predict in a strain, 
considering it can take up to three years for it to emerge as such. Pulling information from 
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GenBank, which is where public health officials post genetic sequences of new flu strains, the 
scientists utilized multidimensional scaling to create graphical plots of complex data. This 
allows them to pare down a 329-amino-acid region of the flu virus to just two dimensions that 
contain the most useful information. Then, all of the points are plotted as a function of these 
two variables, which is much simpler to work with and highlights clusters of future dominant 
strains (Multidimensional, 2010).  
Current Types of Influenza Vaccines and Recommendations 
Currently, there are two main types of influenza vaccine. The most popular is the trivalent 
inactivated virus (TIV), which contains microbes that have been rendered inert with 
chemicals, heat, or radiation. In this form, the virus cannot cause disease or mutate back to 
such a form. Only the antigens, membrane, and genetic material remain present, which are all 
that is needed to produce a response and thus gain immunity. Another notable benefit of this 
type of vaccine is that it does not require refrigeration since it can be transported in a freeze-
dried state, thus enabling increased access for developing countries. A drawback, however, is 
that these vaccines generally do not produce as strong of an immune response as live vaccines 
(Understanding Vaccines, 2008). 
The second type of flu vaccine is the live attenuated influenza vaccine (LAIV), which 
contains a live form of the virus in a weakened or attenuated form. Again, it is not capable of 
causing the actual disease it is protecting the body against in this state. Being live means that 
the virus is that much similar to the organism the body will actually be exposed to come flu 
season. Therefore, it stimulates a stronger immune response, both on a cellular and humoral 
level. Lifelong immunity may be achieved from significantly fewer doses as compared to 
inactivated virus vaccines. Unfortunately, the LAIV has its downfalls, such as the possibility 
of the virus mutating back to its fully virulent form. Unlike the TIV, it must be refrigerated 
and is therefore not as easily accessible in other countries. Also, this vaccine is not 
appropriate for those with compromised immune systems (such as the sick, infants, and the 
elderly). In fact, it is only approved for use in healthy people 2 through 49 years of age who 
are not pregnant (Key Facts, 2013).   
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Once the vaccine has been manufactured, the FDA requires rigorous research and testing 
before permitting the vaccine to be licensed. The first stage is lab and animal testing, also 
called preclinical testing. Only if it meets expectations and appears safe will it be considered 
for clinicsl tesing in humans. Before this can occur,an Investigational New Drug (IND) 
application must be submitted to and approved by the FDA. Only at this point can it be tested 
in human volunteers. The clinical trials start on a small scale; their increase is contingent upon 
the success of the vaccine. Once three phases of the clinical trial occur, testing the safety, 
dosage, and efficacy of the vaccine, an application for license can be submitted to the FDA 
(Understanding Vaccines, 2008). Of course, researchers cannot deliberately expose volunteers 
to pathogens to test efficacy, nor are they required to have a control group for testing. In other 
words, it is deemed unethical to only vaccinate half the study volunteers and not offer them 
the best possible protection from the flu. Therefore, all of the volunteers are vaccinated and 
then monitored throughout the flu season to gauge how well the vaccine prevented them from 
falling ill (Miller, 2002). The last step is to distribute the virus’s information to manufacturers 
and begin production and distribution. For many years, only a few manufacturers were 
producers of the flu vaccine, essentially monopolizing the market on vaccine production. 
However, there were six different manufacturers of TIV this past flu season (2012-2013), as 
well as one manufacturer each for the TIV high dose, TIV intradermal, and LAIV (Seasonal, 
2013) (see Appendix A).  
The current recommendation given by the Advisory Committee on Immunization Practices 
(ACIP), a subdivision of the CDC, is that everyone aged 6 months and over should receive an 
influenza vaccine. One dose is adequate for most people, though it is recommended that 
children under 9 years old who are receiving influenza vaccine for the first time or who 
received only 1 dose the previous season (if it was their first vaccination season) should 
receive 2 doses this season (Kroger, Sumaya, Pickering & Atkinson, 2011). Also, there is a 
high-dose vaccine, Fluzone, approved for use in those 65 and older. It contains 4 times the 
amount of antigen in order to invoke a stronger immune response. However, the ACIP and 
CDC have not expressed an opinion on which dosage is best for the elderly (Fluzone, 2012).  
In 2012, the first meta-analysis assessing efficacy and effectiveness of influenza vaccines 
using sensitive and specific diagnostic tests for influenza was performed. Medline wa sused to 
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find randomized, controlled trials that assessed reduction in influenza risk after receiving a 
vaccination. Articles found to be eligible were  published between January 1, 1967 and 
February 15, 2011. In total, 31 studies over 12 seasons were deemed appropriate for use in the 
meta-analysis. TIV was shown to be efficacious in 67% of the 12 flu seasons analyzed in 
adults aged 18 to 65 years. In children aged 6 months to 17 years, LAIV showed efficacy in 
75% of the seasons. There were no eligible studies for children aged 8 to 17 years, so vaccine 
effectiveness in this group could not be determined. It was concluded that, overall, influenza 
vaccines provide moderate protection in many seasons, but very little in other seasons. 
Protection is even more scarce in the elderly, while young children are the ones who benefit 
most from LAIVs (Osterholm, Kelley, Sommer, & Belongia, 2012).  
Alternative Influenza Vaccine Technology 
Unfortunately, the current vaccine production process takes over six months to complete and 
seems antiquated compared to the great strides that have been reached regarding biomedical 
technology. Aside from this factor, an extremely large supply of fertile chickens and eggs is 
needed. The whole process is centered upon how well the virus grows in the eggs, as well as 
the time that this takes. Therefore, it is nearly impossible to quicken production should a 
pandemic occur.  
On the other hand, growing the virus in living cells rather than eggs (known as cell culture-
based production) is both faster and more precise. Production can also be expanded in the 
case of a pandemic. Another advantage of this method is that it is safe for those with allergies 
to eggs. Although cell culture-based vaccines are available for most other viruses, such as 
measles, mumps, and polio, the same cannot be said of the flu virus. Scientists have 
encountered problems achieving good quality virus yields using the cell culture method, 
though there is one flu vaccine of this kind licensed for use in Europe. Currently, much time 
and effort is being put into producing this type of flu vaccine here in the U.S. (Optimizing, 
2011).  
One promising type of technology is found in DNA-based vaccines, which are advantageous 
in that they do not require the whole influenza virus to be replicated. Instead, they contain a 
portion of the flu virus’ genetic material that is placed inside a plasmid, or circular strand of 
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DNA. Once the vaccine is administered, the genetic material is expressed inside a human cell. 
This leads to the synthesis of flu virus proteins inside the cell, which signals the immune 
system to respond just as an antigen would. This type of vaccine is currently in several stages 
of development for diseases such as the flu (New, 2011).  
A second type of new technology is the subunit vaccine, which is similar to the DNA-based 
vaccine since it usually only includes the immune-stimulating antigens of a virus rather than 
the virus molecules in their entirety (Janeway & Travers, 1996). Identifying which antigens 
will be most effective is the challenge of this method, but once this has been accomplished, 
the antigens can be produced using recombinant DNA technology in the lab. In this way, 
recombinant subunit vaccines differ from DNA-based vaccine since the antigen is made in the 
lab and then injected, rather than being produced by the host cells. The process begins with 
the hemagglutinin gene of the influenza virus, which is responsible for binding the virus to the 
cell it is infecting. This genetic material is then placed into a vector, which is a virus that can 
only infect other species, such as insects, but is harmless to humans. The vector is then used 
to deliver the genetic material to a cell culture in the lab. These cells are instructed by the 
genetic material to produce the antigens, which are then purified and inserted into the vaccine 
(New, 2011). The first successful vaccine of this kind was for the hepatitis B virus (Janeway 
& Travers, 1996). 
Vectors can also be utilized in a different form. Rather than using the vector as an 
intermediary step, the entire vector and influenza genetic material may be injected into a 
patient. Since the vector is a harmless microbe, this method is completely safe, though it may 
seem unnerving to some. Once inside the body, this vector virus will express the 
hemagglutinin proteins needed to induce an immune response (New, 2011).  
Perhaps the most promising vaccine of its kind is the universal flu vaccine, which would 
ideally protect against all influenza strains for an extended period of time, such as over 
decades. The key behind this type of vaccine would be the use of proteins that are present in 
all types of flu, rather than proteins that are specific to a certain subtype and strain. Some of 
these include portions of the hemagglutinin protein, viral envelope proteins like M2, and the 
NP protein, used for viral replication. The hope is that the antibodies produced by the body 
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upon exposure to these antigens would then recognize subsequent strains and be able to stave 
off infection. The NIAID was successful in creating and testing a universal flu vaccine in 
2010, which did indeed produce antibodies in mice, ferrets, and monkeys based on the 
hemagglutinin stem (New, 2011). Dr. Gary J. Nabel, head researcher on this study, noted that 
the stem appears nearly identical in all strains, making it a great target for this vaccine. In fact, 
the mice and ferrets in the trials produced antibodies to flu strains dating as far back as 1934 
and as recent as 2006 and 2007. As of 2010, Dr. Nabel estimated human trials being three to 
five years away (NIH, 2010).  
More recently, a biopharmacetuical company based in Madison, WI called FluGen has been 
developing their own version of a universal flu vaccine, REDEE FLU. It is desgined to not 
only protect against known strains, but also strains that have yet to circulate. Early results 
were promising, as it accomplished both of these goals. The vaccine makes use of a live 
attenuated vrius that is administered as a nasal mist. Human trials are set to begin in 2014 and 
could be sumbitted to the FDA for approval as soon as 2019, which is a short time frame 
compared to that of other drug applications. FluGen anticipates patients needing a dose of 
their vaccine every three to five years to ensure protection against all strains, which is still less 
often than the yearly dosage recommended for current vaccines (Newman, 2013).  
2003-2004 Influenza Season 
The flu season of 2003-2004 was an important turning point in the history of influenza. It is 
not solely for the season’s strain virulence, or the number of deaths that occurred, but because 
of how the U.S. began to handle this information. Many databases were started that season, 
including the Influenza Hospitalization Surveillance Network (FluSurv-NET) and the 
National Notifiable Diseases Surveillance System (Hall-Baker, et al., 2009). 
One research goal of this paper was to find out which factors directly contributed to the large 
increase and subsequent elevation in early childhood (under five years of age) deaths due to 
influenza beginning with the 2003-2004 flu season. Specifically, from 2002 to 2003, this 
number increased from 12 to 90, and has remained high ever since at around 30-40 deaths 
annually. This increase in childhood deaths due to influenza can be seen in the first chart 
below and compared to overall deaths (see Figures 2 and 3), created from the CDC’s annual 
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mortality reports. Concerns have been raised because this increase coincides with the ACIP’s 
encouragement to vaccinate children aged 6-23 months against influenza beginning in the 
2002-2003 flu season. They later upgraded this to a recommendation for the 2004-2005 flu 
season (Eisenberg, et al., 2008). 
 
Figure 2 – Influenza Deaths in Children Under Age 5 (1999-2008) 
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Figure 3 – Influenza Deaths, All Ages (2002-2008) 
Overall, there were multiple causes behind the elevated death rate during this time. First of 
all, the vaccine was poorly matched to the actual strain of flu virus that prevailed in that 
season. The A (H3N2) subtype chosen for the flu vaccine based on past seasons was 
A/Panama/2007/99 (an A/Moscow/99 virus). This strain, however, was not the one that 
prevailed and sickened most people that year. Instead, it was A/Fujian/411/2002 that 
dominated, unfortunately not one of the strains in the vaccine. Late reports by WHO showed 
that virus isolates were different from A/Panama/2007/99 and closely related to 
A/Fujian/411/2002. Unfortunately, there was no virus similar to the latter strain that had been 
isolated in eggs, so the decision was made to include the next most promising strain, 
A/Panama/2007/99. Because of this mismatch, the vaccine lost a great deal of its potential 
effectiveness (Recommendations, 2003) (see Appendix B).  
A study by Eisenberg et al. (2008) was conducted to discern the efficacy of the influenza 
vaccine in children aged 6-59 months during both the 2003-2004 and 2004-2005 flu seasons 
in more depth. Case studies were conducted on children who had tested positive for influenza, 
as well as control children who had tested negative. Demographic information was gleaned 
through patient records and parental interviews. It was determined that, in both years, there 
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was a “suboptimal” match between the circulating and vaccine influenza strains. Around 19% 
of the children in the study were fully vaccinated against influenza for both years. Statistical 
analysis showed that full vaccination was associated with “significantly fewer influenza-
related inpatient, emergency department, or outpatient clinic visits in 2004–2005” and had an 
effectiveness of 57%. This was not the case in 2003-2004, however, in which the vaccine 
effectiveness was only 44%. In both years, partial vaccination was not effective (Eisenberg, et 
al., 2008). Although this study did not compare vaccination rates to death rates directly, the 
conclusion regarding the 2003-2004 vaccine supports the idea that it failed to adequately 
protect the recipients from influenza and subsequent deaths.  
Secondly, the vaccination rate in children was still extremely low even after the 
encouragement to vaccinate. A study done by Santibanez et al. (2006) compared influenza 
vaccine rates in children aged 6 to 23 months during the 2002-2003 and 2003-2004 flu 
seasons using the National Immunization Survey. Two measures were included: those who 
had received one or more influenza vaccinations during September to December of the given 
flu season, and those who had been fully vaccinated (two doses if they had never been 
vaccinated against influenza before) between September and January. Demographics of each 
child’s family were noted. As for the analysis, weighted adjustments were made to determine 
a national estimate, and statistical tests were run to search for any significance between 
influenza vaccination status and certain demographic and immunization-provider features. 
Results showed that during the 2002-2003 and 2003-2004 flu seasons, 7.4% and 17.5% 
(respectively) of children aged 6 to 23 months received at least one dose of influenza vaccine. 
It was also noted that, of these children, 40% and 52%, respectively, did not receive a second 
dose to be considered fully vaccinated. This means that vaccine coverage was fairly poor over 
both of the seasons, which may point to other causes of death besides the vaccines 
themselves. Disparities among demographics were found as well, highlighting lower maternal 
education, a large number of children per household, receiving vaccines at public clinics, and 
being of African American race as factors correlating with lower vaccination coverage 
(Santibanez, Santoli, Bridges, & Euler, 2006). The vaccine rate significantly increased after 
encouragement, but was still less than 20% (Hemingway & Poehling). 
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One study conducted by Bhat and Wright (2005) did specifically analyze characteristics of the 
children who died from the 2003-2004 flu, including their vaccination status. Of the 153 
children under eighteen who passed away, the median age was three. For those younger than 
six months old, mortality rates were highest. 24% of 102 children tested positive for bacterial 
co-infections, while 33% had an underlying medical condition known to raise the chance of 
influenza-related complications. Only 16% or eighteen children who died of flu had been 
vaccinated with one dose of the flu vaccine. Of those, only eight had been fully vaccinated 
(Bhat, et al., 2005). Therefore, it is highly unlikely that there was any connection between the 
vaccine and the increase and deaths. The main cause, consequently, can be attributed to the 
virulence of the strain that year (A/H3N2) and the lack of antibodies present in the immature 
immune systems of children. 
Interestingly, there were some regional discrepancies in the data reported by Bhat and Wright 
(2005). As seen below, almost half of all childhood influenza-related deaths occurred in the 
South. The other half was split between the West and Midwest, while the Northeast accounted 
for just 8% of deaths (see Figure 4).  
 
Figure 4 – Regional Childhood Flu Deaths, 2003-2004 
METHODOLOGY 
Upon noticing the regional discrepancies in death tolls, this became a new area of interest to 
explore. Namely, were there in fact regional differences that are sustained over time, or was 
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this an anomaly? More importantly though, how effective is the flu vaccine in children? The 
first approach chosen to answer these questions was to compare childhood flu vaccine 
coverage rates and death rates due to flu in each state. Unfortunately, after searching the 
National Immunization Survey (NIS) database, CDC, and visiting the Rhode Island 
Department of Health, it was determined that there was not enough mortality data to 
effectively conduct this analysis. The following factors were to blame: 
 Very few or no childhood deaths in some states (such as Rhode Island) 
 Inconsistent age ranges between the two types of data 
 Inconsistent regional groupings between the two groups of data 
 Inconsistent time periods (some data was listed by year, while other data was 
categorized by flu season, which would yield two very different figures) 
 
This led to the first change made to the type of data being used in the analysis. At the 
suggestion of analysts at the Rhode Island DOH, hospitalization rates due to influenza were 
used instead of death rates, since there would be much more to work with. However, this too 
soon proved futile. The only consistent, publically available vaccine coverage data available 
is from the NIS, which only measured the coverage rates in children aged 6 to 23 months until 
recently (2008), as mentioned previously. The hospitalization data found through Healthcare 
Cost and Utilization Project (HCUP), on the other hand, categorized children as 0-17 years of 
age in their statewide database, which was obviously too large of a span to compare to the 
vaccine coverage data. (It was not until 2010 that the CDC gathered and posted data for more 
current seasons using FluView as their medium, which listed young children as 6 months to 4 
years of age.)  
Once again, it was necessary to explore another measure of the flu’s impact. This time, U.S. 
influenza-like illness (ILI) outpatient visits due to flu were used as this indicator. Specifically, 
this data came from regional ILI visits reported by ILI Surveillance Network (ILINet) 
providers. It was classified by Health and Human Services (HHS) regions of the U.S (see 
Appendix C). Unfortunately, NIS data for vaccine coverage was not consistent between 
seasons, and instead either provided counts by years rather than seasons or omitted flu vaccine 
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rates altogether. The only seasons with the necessary data available over the last decade were 
2003-2004, 2009-2010, 2010-2011, and 2011-2012. Also, national vaccine coverage and 
outpatient rates for seven flu seasons (2002-2009) were compared in a final analysis. 
For the first four regional analyses, data was gathered from both the NIS and ILINet. 
Although the NIS data was already in terms of a rate, the outpatient data on ILINet was not. 
In order to remedy this, it was deemed appropriate to create outpatient rates based on total 
regional populations. Unfortunately, these figures are not readily accessible since the U.S. 
Census does not split regional population by the same age range as the NIS. In order to 
estimate these numbers, the national percentage of 0-4 year olds in both the 2000 and 2010 
censuses (6.81% and 6.50%, respectively) was multiplied by total regional populations for 
each of the ten regions (see Appendix D). 
Next, the vaccine coverage rates by region were treated as the X variable, while the outpatient 
rates by region were treated as the Y variable for graphing purposes. Using Excel, the data 
points were plotted as a scatterplot on an X-Y axis, and a linear trendline was fitted to the ten 
data points for each of the four flu seasons. The same was done for the national rates over 
seven seasons (see Figures 5-9 and Appendix E).  
 
Figure 5 – 2003-2004 Childhood Outpatient Flu Visits vs. Flu Vaccine Coverage By Region 
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Figure 6 – 2009-2010 Childhood Outpatient Flu Visits vs. Flu Vaccine Coverage By Region 
 
Figure 7 – 2010-2011 Childhood Outpatient Flu Visits vs. Flu Vaccine Coverage By Region 
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Figure 8 – 2011-2012 Childhood Outpatient Flu Visits vs. Flu Vaccine Coverage By Region 
 
Figure 9 –Childhood Outpatient Flu Visits vs. Flu Vaccine Coverage Over 7 Seasons 
Finally, a regression analysis was conducted on each set of data and tested for statistical 
significance using ANOVA. For each data set, the ANOVA hypotheses were as follows: 
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 H0: The slope is equal to 0 (there is no relationship between childhood flu vaccine 
coverage rates and childhood ILI outpatient rates). 
 HA: The slope is not equal to 0.  
RESULTS & DISCUSSION 
The ANOVA results are summarized in Figure 10 below: 
 
Year F-Value P-Value Significance 
(alpha=0.05) 
2003-2004 0.882 0.37 Not significant (>0.05) 
2009-2010 0.342 0.57 Not significant (>0.05) 
2010-2011 0.289 0.61 Not significant (>0.05) 
2011-2012 1.263 0.29 Not significant (>0.05) 
7 Seasons 11.054 0.02 Significant (<0.05) 
Figure 10 – Results Summary 
 
 
Looking at the R
2
 correlation coefficients for each graph is very telling of the relationship 
strength in each year. The first four graphs all have very low correlation coefficients (close to 
0), meaning that there is no significant relationship between flu vaccine coverage and 
outpatient rates (confirmed by the regression analysis and ANOVA test of significance).  
Upon doing this initial analysis, the graphs were fit to other models in Excel to test whether or 
not this would increase the R
2
. Sure enough, all of the correlations improved a great deal. The 
season that showed the most improvement with a higher-order model was 2010-2011, which 
was fit to a 6
th
 degree polynomial trendline (see Figure 11).  
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Figure 11 – Revised Trendline for 2010-2011 
This reveals that the relationship between vaccination rates and outpatient rates is not strictly 
linear, and may not be a direct relationship. Instead, there may very well be other factors or 
variables influencing the relationship (see Figure 12). These could potentially include the 
overall health and population density of each region. For example, it has been shown in a 
study by Cullen, Cummins, & Fuchs (2012) that geographic disparities among life 
expectancies do exist. Even after adjusting for racial distribution, they are still very significant 
(though there is an additional link between race and life expectancy). The South and heavily 
urban areas have the lowest probabilities of survival to age 70 for all races, though only white 
males are shown (see Figure 13) (Cullens, Cummins, & Fuchs, 2012). This could explain one 
anomaly that exists in Region 2 – New York and Region 3 - Philadelphia. For the last three 
seasons in the analysis (2009-2012), both New York and Philadelphia consistently reported 
above-average outpatient rates, yet also achieved above-average vaccination rates. The higher 
population density and urban atmosphere could be in effect here.  
Two other potential variables are the region’s attitude towards vaccines, as well as their 
accessibility. For example, it could be theorized that because the overall well-being of people 
in the South is lower than average, people are less health-conscious. They may not be aware 
of all the potential benefits of vaccines, or they may simply be closed-minded to them. This 
could explain the low vaccination coverage rate in the South over all flu seasons. As far as 
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accessibility, one example of its effect on vaccine coverage rates is seen in Region 5 – 
Chicago. In three out of the four seasons individually analyzed, Chicago reported lower than 
average vaccination rates, yet also had below-average outpatient rates due to flu. Perhaps this 
area’s vaccination programs for children are not as strong as in the Northeast, which has 
vaccination clinics within schools. Also, the harsh winter weather in the northern area of 
Region 5 may be responsible for decreased accessibility to flu vaccines.  
 
Figure 12 – Potential Factors Influencing Vaccine Coverage/Outpatient Rate Relationship 
 
 
Figure 13 - Probability of Survival to Age 70 for White Males 
Source: (Cullen, Cummins, & Fuchs, 2012) 
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On the other hand, the graph of national rates over seven seasons reveals a moderately strong 
linear relationship with a correlation of 69% and is statistically significant (p=0.02). In other 
words, as childhood flu vaccination coverage rates increase, so do childhood ILI outpatient 
rates. At first thought, this trend seems counter-intuitive. Upon further inspection, it is 
apparent that confounding factors may also exist. Here again, the correlation coefficient 
increased when the data was fit to a high-order polynomial model, which supports this line of 
thought (see Figure 14).  
It may be that increased health awareness overall is causing this seemingly baffling 
relationship. The two sub-factors that contribute to this increased awareness are higher 
vaccination rates and higher outpatient visits (the two variables being studied). Taking it one 
step further, two factors that lead to more doctor visits are improved accessibility of clinics 
and more self-diagnosis tools and inclinations. The advent of walk-in clinics and convenience 
of these facilities compared to doctors’ offices (i.e., closer distance, longer hours) could very 
well be a cause of increased outpatient visits. People are more likely to see a doctor when they 
feel symptoms of the flu since it is much easier now than it once was. In addition, this 
generation may have a more favorable attitude of doctors and taking advantage of the help 
they offer, being more health conscious and aware of the media that supports this view. 
Finally, self-diagnosis via the Internet may be another factor contributing to increased 
outpatient visits. It is very easy for a parent to search their child’s symptoms online and 
become concerned. Ultimately, they decide that these symptoms warrant a doctor visit. All of 
these factors should not necessarily be viewed in a negative or positive light, but may simply 
help explain why childhood ILI outpatient rates increase with flu vaccine coverage rates.  
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Figure 13 - Probability of Survival to Age 70 for White Males 
 
LIMITATIONS 
One main limitation lies in the fact that, although the most consistent data was chosen, the age 
range of the flu vaccine coverage data was 6-23 months of age for some years, while the 
outpatient data was from 0-4 years of age. During the swine flu pandemic, the coverage rates 
were only measured for a larger group of children aged 6 months to 17 years of age. Finally, 
from 2010-2012, the coverage rates were the most similar to the hospitalization rates, the 
former age range being from 6 months to 4 years of age.  
Another limitation is the way in which regional population was calculated in order to 
transform outpatient figures into rates. Because the U.S. Census does not break down regional 
population by age increments as small as 0-4 years of age, this had to be estimated based on 
the national figures. This assumes that the national distribution is the same throughout the 
country, but this may not necessarily be the case. 
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CONCLUSION & NEXT STEPS 
The conclusion of this capstone is not meant to be a definitive answer on whether or not 
influenza vaccines are effective, or even the extent to which they are so. Rather, the emphasis 
should be on the fact that there was no direct, linear relationship between childhood influenza 
vaccination rates and childhood ILI outpatient rates. There is potential for expanded studies 
on what confounding factors may be contributing to this relationship. On the other hand, 
although national flu vaccination and outpatient rates in children did reveal a positive, 
significant relationship, this also must be examined below the surface for additional factors. It 
is too easy to fall into the trap of taking data at face value, such as when it is presented by the 
media.  
The many obstacles faced throughout this capstone regarding data accessibility and 
presentation underscores the need for enhanced public health communications. It is crucial 
that parents have the necessary information to make informed immunization decisions for 
both themselves and their children. Thus, further analysis is called for in order to present a 
clear picture to the public. With health awareness on the rise, there is a great yearning for this 
void to be filled.  
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APPENDICES 
Appendix A – Influenza Manufacturers 
 
Influenza Vaccine Information for the 2012-2013 Flu Season 
Vaccine Trade Name Manufacturer 
TIV Fluzone Sanofi Pasteur 
TIV Agriflu Novartis Vaccines 
TIV Fluvirin Novartis Vaccines 
   
TIV Fluarix GlaxoSmithKline 
TIV FluLaval 
ID Biomedical Corporation of Quebec 
(distributed by GlaxoSmithKline) 
TIV Afluria 
CSL Biotherapies (distributed by 
Merck) 
TIV high- 
dose 
Fluzone High-
Dose 
Sanofi Pasteur 
TIV 
intradermal 
Fluzone 
Intradermal 
Sanofi Pasteur 
LAIV FluMist MedImmune 
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Appendix B – Influenza Vaccine Virus Strains By Season 
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Appendix C – HHS Regions 
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Appendix D – Calculation of Regional Populations for Age 0-4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regiona l 
Popula tion 
2000
Regiona l 
Popula tion 2010
0-4 y.o. Popula tion 
2000
0-4 y.o. Popula tion 
2010
Region 1 - Boston 13,922,517 14,444,865 948,665.93                     938,916.23                       
Region 2 - New York 27,390,807 28,169,996 1,866,381.30                  1,831,049.74                    
Region 3 - Philadelphia 27,820,058 29,829,606 1,895,630.02                  1,938,924.39                    
Region 4 - Atlanta 53,252,966 61,082,315 3,628,602.10                  3,970,350.48                    
Region 5 - Chicago 50,074,516 51,725,489 3,412,025.80                  3,362,156.79                    
Region 6 - Dallas 33,263,896 38,405,381 2,266,567.52                  2,496,349.77                    
Region 7 - Kansas City 12,921,216 13,714,741 880,438.31                     891,458.17                       
Region 8 - Denver 9,327,451 10,832,893 635,562.88                     704,138.05                       
Region 9 - San Francisco 42,212,074 47,706,825 2,876,287.12                  3,100,943.63                    
Region 10 - Seattle 11,236,405     12,833,427                765,637.03                     834,172.76                       
281,421,906 308,745,538 19,175,798.00        20,068,459.97         
6.81% 6.50%
Percent of 0-4 yr 
olds in the US, 
Percent of 0-4 yr olds 
in the US, 2010:
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Appendix E – Data 
 
Note: 
 Green=low outpatient, high vaccination coverage (based on whether it was above or below average) 
Red=high outpatient, low vaccination coverage (based on whether it was above or below average) 
 
 
 
 
 
 
2003-2004
Region
Childhood Full 
Dose Flu Vaccine 
Coverage Per 
100,000*
Childhood 
Outpatient ILI Visits 
Per 100,000**
Region 1 - Boston 10,583.33              225.90                    
Region 2 - New  York 5,250.00                190.26                    
Region 3 - Philadelphia 7,433.33                175.88                    
Region 4 - Atlanta 4,275.00                477.90                    
Region 5 - Chicago 8,266.67                470.86                    
Region 6 - Dallas 3,840.00                180.67                    
Region 7 - Kansas City 8,200.00                334.95                    
Region 8 - Denver 8,933.33                914.46                    
Region 9 - San Francisco 4,000.00                328.76                    
Region 10 - Seattle 5,325.00                113.89                    
AVERAGE 6,610.67                341.35                    
*6-23mo
**0-4yo
2009-2010
Region
Childhood Full 
Dose Flu Vaccine 
Coverage Per 
100,000*
Childhood 
Outpatient ILI Visits 
Per 100,000**
Region 1 - Boston 38,700.00             502.92                     
Region 2 - New  York 38,500.00             2,233.20                  
Region 3 - Philadelphia 34,400.00             1,495.39                  
Region 4 - Atlanta 30,323.18             1,810.95                  
Region 5 - Chicago 32,884.54             781.50                     
Region 6 - Dallas 33,897.26             1,767.56                  
Region 7 - Kansas City 34,506.17             866.50                     
Region 8 - Denver 36,279.52             1,999.96                  
Region 9 - San Francisco 32,030.71             906.59                     
Region 10 - Seattle 31,633.07             477.51                     
AVERAGE 34,315.45             1,284.21                  
*6m-17yo
**0-4yo
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2010-2011
Region
Childhood Full 
Dose Flu Vaccine 
Coverage Per 
100,000*
Childhood 
Outpatient ILI Visits 
Per 100,000**
Region 1 - Boston 62,123.08             752.25                     
Region 2 - New  York 54,778.57             1,958.77                  
Region 3 - Philadelphia 54,010.29             1,037.28                  
Region 4 - Atlanta 46,524.71             1,326.81                  
Region 5 - Chicago 50,007.69             609.52                     
Region 6 - Dallas 48,628.57             1,144.71                  
Region 7 - Kansas City 50,595.74             418.42                     
Region 8 - Denver 52,845.31             639.79                     
Region 9 - San Francisco 48,197.87             682.08                     
Region 10 - Seattle 45,742.55             314.44                     
AVERAGE 51,345.44             888.41                     
*6m-4yo
**0-4yo
2011-2012
Region
Childhood Full 
Dose Flu Vaccine 
Coverage Per 
100,000*
Childhood 
Outpatient ILI 
Visits Per 
100,000**
Region 1 - Boston 63,717.19            700.38                  
Region 2 - New  York 58,051.72            2,184.43               
Region 3 - Philadelphia 55,436.92            921.18                  
Region 4 - Atlanta 50,580.00            930.95                  
Region 5 - Chicago 53,873.13            649.55                  
Region 6 - Dallas 51,887.50            813.03                  
Region 7 - Kansas City 55,273.33            401.48                  
Region 8 - Denver 54,284.62            1,161.42               
Region 9 - San Francisco 51,336.17            498.04                  
Region 10 - Seattle 47,476.60            290.83                  
AVERAGE 54,191.72            855.13                  
*6m-4yo
**0-4yo
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Overall
Year
Childhood 
Full Dose Flu 
Vaccine 
Coverage 
Estimates (%)*
National 
Childhood 
Outpatient ILI 
Visits (%)**
02-03 4.30% 0.16%
03-04 8.00% 0.34%
04-05 18.20% 0.37%
05-06 20.50% 0.37%
06-07 21.00% 0.45%
07-08 23.00% 0.67%
08-09 25.00% 0.76%
AVERAGE 17.14% 0.45%
*6-23mo
**0-4yo
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